An official website of the United States government
Shingles (Herpes Zoster) Vaccination Information for Healthcare Providers
Shingrix Recommendations
ÐÇ¿ÕÓéÀÖ¹ÙÍø vaccination recommendations, and the contraindications and precautions for Shingrix vaccination
Clinical Considerations for Use of Recombinant Zoster Vaccine (RZV, Shingrix) in Immunocompromised Adults Aged ≥19 Years
These clinical considerations are intended to supplement the MMWR policy note published in January 2022.
About the Vaccine
Information about Shingrix vaccine composition, dosage, and administration, and vaccine efficacy, duration of protection, reactogenicity
Frequently Asked Questions About Shingrix
Answers to commonly asked questions about the new shingles vaccine
Storage and Handling
Information about Shingrix vaccine storage and handling
Administering the Vaccine
Information about administering Shingrix with other vaccines, and how to avoid vaccine administration errors
References and Resources
Materials for patients and resources for healthcare providers
Related Pages
- Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022.
- Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines, 2018.
- Shingles Vaccine Information Statement (Shingrix)